Kaken Pharmaceutical

This study looked at how different levels of liver damage affect the way the body handles a single dose of the experimental drug KP-001. Twenty-four adults with either healthy livers or mild to moderate liver problems took part. Researchers measured drug levels in the blood to se…

This study tested whether a new drug called KP-001 affects the heart's electrical activity (QT interval) in 40 healthy adults. Participants received single doses of KP-001, a placebo, or moxifloxacin (a known heart-effect drug) in random order. The goal was to check for heart rhy…

This study looked at how a new drug called KP-001 affects the way the body processes rosuvastatin (a cholesterol drug) and caffeine. It also tested how another drug, fluvoxamine, affects KP-001 levels. The trial involved 38 healthy adults and was designed to gather safety and int…